Centre for Cancer Prevention
Funding Body: Cancer Research UK and ANZ Breast Cancer Trials Group
Principal Investigator: Professor Jack Cuzick
A new trial of extended aromatase inhibitor treatment, metformin and zolendronic acid (bisphophonate) in five year recurrence survivors of ER positive breast cancer at high risk of late recurrence due to being node positive our tumour size >2cm.
Currently funded for a pilot phase for 300 patients, but the full trial will be a multinational trial of 4,500+ patients.